CA2057456A1 - Anti depression pharmaceutical - Google Patents

Anti depression pharmaceutical

Info

Publication number
CA2057456A1
CA2057456A1 CA2057456A CA2057456A CA2057456A1 CA 2057456 A1 CA2057456 A1 CA 2057456A1 CA 2057456 A CA2057456 A CA 2057456A CA 2057456 A CA2057456 A CA 2057456A CA 2057456 A1 CA2057456 A1 CA 2057456A1
Authority
CA
Canada
Prior art keywords
anti depression
pharmaceutical
depression pharmaceutical
nicotinamide
adenine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2057456A
Other languages
French (fr)
Other versions
CA2057456C (en
Inventor
Jorg Birkmayer
Walther Birkmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2057456A1 publication Critical patent/CA2057456A1/en
Application granted granted Critical
Publication of CA2057456C publication Critical patent/CA2057456C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Use of nicotinamide-adenine-dinucleotide, nicotinamide-adenine-dinucleotide phosphate or a physiologically compatible salt thereof for the treatment of depressions.
CA002057456A 1991-01-04 1991-12-10 Anti depression pharmaceutical Expired - Fee Related CA2057456C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4100361A DE4100361C1 (en) 1991-01-04 1991-01-04
DEP4100361.6 1991-01-04

Publications (2)

Publication Number Publication Date
CA2057456A1 true CA2057456A1 (en) 1992-07-05
CA2057456C CA2057456C (en) 1996-02-06

Family

ID=6422686

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002057456A Expired - Fee Related CA2057456C (en) 1991-01-04 1991-12-10 Anti depression pharmaceutical

Country Status (15)

Country Link
EP (1) EP0493861B1 (en)
JP (1) JP2519148B2 (en)
AT (1) ATE148991T1 (en)
AU (1) AU631755B2 (en)
BR (1) BR9105183A (en)
CA (1) CA2057456C (en)
DE (2) DE4100361C1 (en)
DK (1) DK0493861T3 (en)
ES (1) ES2097181T3 (en)
GR (1) GR3022724T3 (en)
HU (1) HU213112B (en)
IE (1) IE914477A1 (en)
NO (1) NO179602C (en)
PT (1) PT99962B (en)
ZA (1) ZA9244B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654288A (en) * 1995-01-17 1997-08-05 Birkmayer Pharmaceuticals, Inc. Stable NADH and NADPH compositions for sublingual administration
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2953842A1 (en) * 2023-07-17 2023-11-16 Nuadi Europe S L DUST HUBCAPS (Machine-translation by Google Translate, not legally binding)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341412A (en) * 1966-03-04 1967-09-12 Enzomedic Lab Inc Methods of treating schizophrenia
US4970200A (en) * 1988-03-01 1990-11-13 Schering Aktiengesellschaft Agent for treatment of Parkinson's disease

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654288A (en) * 1995-01-17 1997-08-05 Birkmayer Pharmaceuticals, Inc. Stable NADH and NADPH compositions for sublingual administration
US5750512A (en) * 1995-01-17 1998-05-12 Birkmayer Pharmaceuticals, Inc. NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
US5952312A (en) * 1995-01-17 1999-09-14 Birkmayer Pharmaceuticals, Inc. NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension

Also Published As

Publication number Publication date
HU213112B (en) 1997-02-28
HU9200025D0 (en) 1992-03-30
EP0493861A3 (en) 1993-03-03
DE59108553D1 (en) 1997-03-27
GR3022724T3 (en) 1997-06-30
CA2057456C (en) 1996-02-06
ATE148991T1 (en) 1997-03-15
DE4100361C1 (en) 1992-04-23
NO179602C (en) 1996-11-13
PT99962A (en) 1993-02-26
JP2519148B2 (en) 1996-07-31
BR9105183A (en) 1992-09-29
EP0493861A2 (en) 1992-07-08
AU9010991A (en) 1992-07-16
EP0493861B1 (en) 1997-02-19
AU631755B2 (en) 1992-12-03
HUT60141A (en) 1992-08-28
ES2097181T3 (en) 1997-04-01
NO179602B (en) 1996-08-05
ZA9244B (en) 1992-10-28
PT99962B (en) 1999-06-30
NO920056D0 (en) 1992-01-03
DK0493861T3 (en) 1997-08-25
JPH05139978A (en) 1993-06-08
NO920056L (en) 1992-07-06
IE914477A1 (en) 1992-07-15

Similar Documents

Publication Publication Date Title
CA2170647A1 (en) Multiple unit tableted dosage form i
CA2166483A1 (en) New Pharmaceutical Formulation
CA2194167A1 (en) Hair-growing agent
CA2029524A1 (en) Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
CA2154424A1 (en) 1-phenyl-3-dimethylaminopropane compounds having a pharmaceutical effect
AU7338791A (en) Medical valve
CA2254833A1 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
CA2264097A1 (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
CA2212058A1 (en) Preparation and use of a specific gaba-a.alpha.5 receptor ligand for treatment of alzheimer's disease
CA2125662A1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
AU7060896A (en) Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
DE69631609D1 (en) Tricyclische erythromycinderivate
AU2710892A (en) Cytotoxic bicyclo (7.3.1) tridec-4-ene-2,6-diyne compounds and process for the preparation thereof
CA2041417A1 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
CA2118030A1 (en) Drug for increasing the level of testosterone in the body
CA2046069A1 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
CA2301706A1 (en) Use of phanquinone for the treatment of alzheimer's disease
AU3728095A (en) Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
AU4556096A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use as a medicament or diagnostic, and medicament containing them
USD321055S (en) Caliper for dental implants
EP0592903A3 (en) Use of ancrod for the preparation of drugs for the treatment of restenosis.
CA2057456A1 (en) Anti depression pharmaceutical
CA2260863A1 (en) Treatment of psychotic disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed